|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar :
|
|
3
|
Chen WQ, Zhang SW, Zou XN and Zhao P:
Cancer incidence and mortality in China, 2006. Chin J Cancer Res.
23:3–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Simmonds PC, Primrose JN, Colquitt JL,
Garden OJ, Poston GJ and Rees M: Surgical resection of hepatic
metastases from colorectal cancer: A systematic review of published
studies. Br J Cancer. 94:982–999. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yokota M, Kojima M, Nomura S, Nishizawa Y,
Kobayashi A, Ito M, Ochiai A and Saito N: Clinical impact of
elastic laminal invasion in colon cancer: Elastic laminal
invasion-positive stage II colon cancer is a high-risk equivalent
to stage III. Dis Colon Rectum. 57:830–838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glehen O, Osinsky D, Cotte E, et al:
Intraperitoneal chemohyperthermia using a closed abdominal
procedure and cytoreductive surgery for the treatment of peritoneal
carcinomatosis: Morbidity and mortality analysis of 216 consecutive
procedures. Ann Surg Oncol. 10:863–869. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aghili M, Izadi S, Madani H and Mortazavi
H: Clinical and pathological evaluation of patients with early and
late recurrence of colorectal cancer. Asia Pac J Clin Oncol.
6:35–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Medina-Villaamil V, Martínez-Breijo S,
Portela-Pereira P, Quindós-Varela M, Santamarina-Caínzos I,
Antón-Aparicio LM and Gómez-Veiga F: Circulating MicroRNAs in blood
of patients with prostate cancer. Actas Urol Esp. 38:633–639.
2014.In English, Spanish. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang M, Liu R, Sheng J, Liao J, Wang Y,
Pan E, Guo W, Pu Y and Yin L: Differential expression profiles of
microRNAs as potential biomarkers for the early diagnosis of
esophageal squamous cell carcinoma. Oncol Rep. 29:169–176.
2013.
|
|
10
|
Leite KR, Tomiyama A, Reis ST,
Sousa-Canavez JM, Sañudo A, Camara-Lopes LH and Srougi M: MicroRNA
expression profiles in the progression of prostate cancer – from
high-grade prostate intraepithelial neoplasia to metastasis. Urol
Oncol. 31:796–801. 2013. View Article : Google Scholar
|
|
11
|
He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan
FK, Sung JJ and Yu J: MicroRNA-218 inhibits cell cycle progression
and promotes apoptosis in colon cancer by downregulating BMI1
polycomb ring finger oncogene. Mol Med. 18:1491–1498.
2012.PubMed/NCBI
|
|
12
|
Heckmann D, Maier P, Laufs S, et al: The
disparate twins: A comparative study of CXCR4 and CXCR7 in
SDF-1α-induced gene expression, invasion and chemosensitivity of
colon cancer. Clin Cancer Res. 20:604–616. 2014. View Article : Google Scholar
|
|
13
|
Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao
X, Jia W and Huang J: Decreased expression of miR-218 is associated
with poor prognosis in patients with colorectal cancer. Int J Clin
Exp Pathol. 6:2904–2911. 2013.PubMed/NCBI
|
|
14
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu YZ, Wu K, Huang J, et al: The
PTEN/PI3K/Akt and Wnt/β-catenin signaling pathways are involved in
the inhibitory effect of resveratrol on human colon cancer cell
proliferation. Int J Oncol. 45:104–112. 2014.PubMed/NCBI
|
|
16
|
Jiang QG, Li TY, Liu DN and Zhang HT:
PI3K/Akt pathway involving into apoptosis and invasion in human
colon cancer cells LoVo. Mol Biol Rep. 41:3359–3367. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao ZM, Wang XY and Wang AM: Periostin
induces chemo-resistance in colon cancer cells through activation
of the PI3K/Akt/survivin pathway. Biotechnol Appl Biochem. Dec
24–2013.Epub ahead of print. View
Article : Google Scholar
|
|
18
|
Josse C, Bouznad N, Geurts P, Irrthum A,
Huynh-Thu VA, Servais L, Hego A, Delvenne P, Bours V and Oury C:
Identification of a microRNA landscape targeting the PI3K/Akt
signaling pathway in inflammation-induced colorectal
carcinogenesis. Am J Physiol Gastrointest Liver Physiol.
306:G229–G243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong M, Yang G, Liu H, Liu X, Lin S, Sun D
and Wang Y: Aged black garlic extract inhibits HT29 colon cancer
cell growth via the PI3K/Akt signaling pathway. Biomed Rep.
2:250–254. 2014.PubMed/NCBI
|
|
20
|
Li XX, Huang LY, Peng JJ, Liang L, Shi DB,
Zheng HT and Cai SJ: Klotho suppresses growth and invasion of colon
cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway.
Int J Oncol. 45:611–618. 2014.PubMed/NCBI
|
|
21
|
Nuvoli B, Santoro R, Catalani S,
Battistelli S, Benedetti S, Canestrari F and Galati R: CELLFOOD™
induces apoptosis in human mesothelioma and colorectal cancer cells
by modulating p53, c-myc and pAkt signaling pathways. J Exp Clin
Cancer Res. 33:242014. View Article : Google Scholar
|
|
22
|
Enayat S, Ceyhan MS, Başaran AA, Gürsel M
and Banerjee S: Anticarcinogenic effects of the ethanolic extract
of Salix aegyptiaca in colon cancer cells: Involvement of Akt/PKB
and MAPK pathways. Nutr Cancer. 65:1045–1058. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Trigka EA, Levidou G, Saetta AA, et al: A
detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway
in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN
mutational status and clinicopathological features. Oncol Rep.
30:623–636. 2013.PubMed/NCBI
|
|
24
|
Banerjee N, Kim H, Talcott S and
Mertens-Talcott S: Pomegranate polyphenolics suppressed
azoxymethane-induced colorectal aberrant crypt foci and
inflammation: Possible role of miR-126/VCAM-1 and
miR-126/PI3K/AKT/mTOR. Carcinogenesis. 34:2814–2822. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pandurangan AK: Potential targets for
prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt
pathways. Asian Pac J Cancer Prev. 14:2201–2205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seo BR, Min KJ, Cho IJ, Kim SC and Kwon
TK: Curcumin significantly enhances dual PI3K/Akt and mTOR
inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma
Caki cells through down-regulation of p53-dependent Bcl-2
expression and inhibition of Mcl-1 protein stability. PLoS One.
9:e955882014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zang C, Eucker J, Liu H, Müller A,
Possinger K and Scholz CW: Concurrent inhibition of PI3-kinase and
mTOR induces cell death in diffuse large B cell lymphomas, a
mechanism involving down regulation of Mcl-1. Cancer Lett.
339:288–297. 2013. View Article : Google Scholar
|
|
28
|
Kampa-Schittenhelm KM, Heinrich MC, Akmut
F, Rasp KH, Illing B, Döhner H, Döhner K and Schittenhelm MM: Cell
cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor
NVP-BGT226 in acute leukemia. Mol Cancer. 12:462013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Müller A, Zang C, Chumduri C, Dörken B,
Daniel PT and Scholz CW: Concurrent inhibition of PI3K and
mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis
by down-regulation of Mcl-1 in mantle cell lymphoma. Int J Cancer.
133:1813–1824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Malinowsky K, Nitsche U, Janssen KP, Bader
FG, Späth C, Drecoll E, Keller G, Höfler H, Slotta-Huspenina J and
Becker KF: Activation of the PI3K/AKT pathway correlates with
prognosis in stage II colon cancer. Br J Cancer. 110:2081–2089.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Uesugi A, Kozaki K, Tsuruta T, Furuta M,
Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive
microRNA miR-218 targets the mTOR component Rictor and inhibits AKT
phosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li
S, Zhou J and Yuan F: microRNA-218 increase the sensitivity of
gastrointestinal stromal tumor to imatinib through PI3K/AKT
pathway. Clin Exp Med. Apr 5–2014.Epub ahead of print. View Article : Google Scholar
|
|
33
|
Hadler-Olsen E, Winberg JO and
Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as
diagnostic and prognostic markers and therapeutic targets. Tumour
Biol. 34:2041–2051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stellas D and Patsavoudi E: Inhibiting
matrix metalloproteinases, an old story with new potentials for
cancer treatment. Anticancer Agents Med Chem. 12:707–717. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shuman Moss LA, Jensen-Taubman S and
Stetler-Stevenson WG: Matrix metalloproteinases: Changing roles in
tumor progression and metastasis. Am J Pathol. 181:1895–1899. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tie J, Pan Y, Zhao L, et al: MiR-218
inhibits invasion and metastasis of gastric cancer by targeting the
Robo1 receptor. PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL
and Yao GL: Reduced expression of circulating microRNA-218 in
gastric cancer and correlation with tumor invasion and prognosis.
World J Gastroenterol. 20:6906–6911. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kinoshita T, Hanazawa T, Nohata N, et al:
Tumor suppressive microRNA-218 inhibits cancer cell migration and
invasion through targeting laminin-332 in head and neck squamous
cell carcinoma. Oncotarget. 3:1386–1400. 2012.PubMed/NCBI
|
|
39
|
Yamamoto N, Kinoshita T, Nohata N, Itesako
T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N: Tumor
suppressive microRNA-218 inhibits cancer cell migration and
invasion by targeting focal adhesion pathways in cervical squamous
cell carcinoma. Int J Oncol. 42:1523–1532. 2013.PubMed/NCBI
|
|
40
|
Hassan MQ, Maeda Y, Taipaleenmaki H, et
al: miR-218 directs a Wnt signaling circuit to promote
differentiation of osteoblasts and osteomimicry of metastatic
cancer cells. J Biol Chem. 287:42084–42092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo F, Carter DE and Leask A: miR-218
regulates focal adhesion kinase-dependent TGFβ signaling in
fibroblasts. Mol Biol Cell. 25:1151–1158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Knight ZA, Gonzalez B, Feldman ME, et al:
A pharmacological map of the PI3-K family defines a role for
p110alpha in insulin signaling. Cell. 125:733–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hales EC, Taub JW and Matherly LH: New
insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling
axis: Targeted therapy of γ-secretase inhibitor resistant T-cell
acute lymphoblastic leukemia. Cell Signal. 26:149–161. 2014.
View Article : Google Scholar
|
|
44
|
Serrano-Nascimento C, da Silva Teixeira S,
Nicola JP, Nachbar RT, Masini-Repiso AM and Nunes MT: The acute
inhibitory effect of iodide excess on sodium/iodide symporter
expression and activity involves the PI3K/Akt signaling pathway.
Endocrinology. 155:1145–1156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim SM, Park JH, Kim KD, Nam D, Shim BS,
Kim SH and Ahn KS, Choi SH and Ahn KS: Brassinin induces apoptosis
in PC-3 human prostate cancer cells through the suppression of
PI3K/Akt/mTOR/S6K1 signaling cascades. Phytother Res. 28:423–431.
2014. View Article : Google Scholar
|
|
46
|
Jung KH, Yan HH, Fang Z, Son MK, Lee H,
Hong S and Hong SS: HS-104, a PI3K inhibitor, enhances the
anticancer efficacy of gemcitabine in pancreatic cancer. Int J
Oncol. 45:311–321. 2014.PubMed/NCBI
|
|
47
|
Slotkin EK, Patwardhan PP, Vasudeva SD, de
Stanchina E, Tap WD and Schwartz GK: MLN0128, an ATP-competitive
mTOR kinase inhibitor with potent in vitro and in vivo antitumor
activity, as potential therapy for bone and soft-tissue sarcoma.
Mol Cancer Ther. 14:395–406. 2015. View Article : Google Scholar
|
|
48
|
Yuan H, Yang P, Zhou D, Gao W, Qiu Z, Fang
F, Ding S and Xiao W: Knockdown of sphingosine kinase 1 inhibits
the migration and invasion of human rheumatoid arthritis
fibroblast-like synoviocytes by down-regulating the PI3K/AKT
activation and MMP-2/9 production in vitro. Mol Biol Rep.
41:5157–5165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang N, Hui L, Wang Y, Yang H and Jiang X:
SOX2 promotes the migration and invasion of laryngeal cancer cells
by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep.
31:2651–2659. 2014.PubMed/NCBI
|
|
50
|
Su Y, Gao L, Teng L, Wang Y, Cui J, Peng S
and Fu S: Id1 enhances human ovarian cancer endothelial progenitor
cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways.
J Transl Med. 11:1322013. View Article : Google Scholar
|
|
51
|
Li X, Yang Z, Song W, et al:
Overexpression of Bmi-1 contributes to the invasion and metastasis
of hepatocellular carcinoma by increasing the expression of matrix
metalloproteinase (MMP)-2, MMP-9 and vascular endothelial growth
factor via the PTEN/PI3K/Akt pathway. Int J Oncol. 43:793–802.
2013.PubMed/NCBI
|
